by EpicentRx | Dec 6, 2022 | Blog
Interested in a wicked good analogy? Well look no further than the 30-minute presentation given by Drs. Bryan Oronsky and Richard Gordon at the 2022 Inflammasome Therapeutics Summit in Boston, Massachusetts. In the presentation, Dr. Oronsky compared inflammation to...
by EpicentRx | Dec 6, 2022 | 2022, Press Releases
Dual anti-cancer and radio/chemoprotective agent reduces toxicity from radiation exposure Torrey Pines, Calif., December 6, 2022 – EpicentRx Inc. (“EpicentRx”), a leading-edge, clinical stage biopharmaceutical company that uses groundbreaking science to treat...
by EpicentRx | Nov 30, 2022 | Feature Blog
William Coley, often regarded as the “Father of Immunotherapy”, was a bone sarcoma surgeon in New York from 1890-1936. He is famous for having developed a cocktail of heat-killed bacteria that came to be known derogatorily as “Coley’s Toxins”, which he used to treat...
by EpicentRx | Nov 29, 2022 | 2022, Press Releases
The funding will support study of lead small molecule inflammasome inhibitor in MND, also known as amyotrophic lateral sclerosis (ALS) Torrey Pines, Calif. and Queensland, Australia, Nov. 29, 2022 /PRNewswire/ – EpicentRx Inc. (“EpicentRx”), a...
